Daiichi Sankyo, a major pharmaceutical company that is developing a domestic vaccine for the new coronavirus, announced that it has started clinical trials on a scale of 4,500 people in order to apply for approval of the "mRNA vaccine" under development for booster vaccination. bottom.
This was announced on the 26th by Daiichi Sankyo, which is developing an "mRNA vaccine" with its own technology for the new coronavirus.
The clinical trial targeted approximately 4,500 people aged 18 years and older who had already been vaccinated twice, with the third booster vaccination under development and the Pfizer and Moderna "mRNA vaccine" boosters. It is to check whether the efficacy is equivalent and whether there is a problem in safety by comparing the cases.
According to the company, a similar clinical trial with about 500 people prior to this confirmed that it was as effective as other vaccines.
Based on the results of this clinical trial on a scale of 4,500 people, Daiichi Sankyo has a policy of applying for approval to the national government for booster vaccination, aiming for practical application during this time.